Citizens JMP downgraded Astria Therapeutics (ATXS) to Market Perform from Outperform without a price target afire after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm views it as highly likely that the transaction will close as announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- BioCryst reinstated with a Buy at TD Cowen
- Astria Therapeutics downgraded to Perform from Outperform at Oppenheimer
- BioCryst weakness presents ‘compelling’ buying opportunity, says RBC
- Strategic Acquisition of Astria Therapeutics by BioCryst Pharmaceuticals Highlights Potential of Navenibart for HAE Prophylaxis
- BioCryst price target raised to $15 from $14 at Jefferies